Introduction
Lipoatrophy at injection sites is a common complication of treatment with insulin and has been reported in 10%,' 24o%,2 and 55%3 of patients treated with conventional bovine insulins. Many theories have been proposed, but the exact pathogenesis remains obscure. Lipoatrophy is almost unknown in patients treated only with highly purified porcine insulins,' which prompted us to examine the role of immunological factors in its pathogenesis.
Patients and methods
We studied one man and 13 women with moderate or severe lipoatrophy. Their mean age was 45 years (range ) and the mean University Hospital, Nottingham NG7 2UH W G REEVES, BSC, FRCP, consultant immunologist and senior lecturer BR ALLEN, MB, MRtcP, consultant dermatologist R B TATTERSALL, m.D, MRcp, consultant physician duration of treatment with insulin 11 years (range four months to 30 years). Five insulin-treated patients (three women and two men) without evidence of lipoatrophy served as controls; they were younger than the study group (mean age 25 years) but had been treated with insulin for a similar time (mean 10 years) (see table I ). Figure 1 shows the clinical appearance of the lipoatrophy in case 1. Skin biopsy samples were taken from the edge of lipoatrophic areas in eight patients (cases 1-8), from the middle of lipoatrophic areas in three (cases 9-11), and from normal skin distant to injection sites in three (cases [12] [13] [14] . The five control biopsy samples were taken from non-lipoatrophic areas that had recently been repeatedly injected with insulin. Biopsy tissue was snap-frozen in liquid nitrogen. Immunofluorescence analysis was performed as described.5 Cryostat sections were incubated with fluorescein-conjugated antisera specific for IgG, IgA, IgM, Clq, C3, and fibrin-fibrinogen (Dako Immunoglobulins Ltd). Sections were examined in both blue and ultraviolet light with a Leitz Ortholux incident light microscopy system. Insulin was detected with an indirect immunofluorescence technique in which sections were initially incubated with unconjugated guinea-pig antiinsulin serum followed by fluorescein-conjugated anti-guinea-pig immunoglobulin serum (both from Wellcome Reagents Ltd). Normal guinea-pig serum was used as a control in the first stage of this assay. The degree of deposition of immunological components was scored as absent (-) or present (+, + +, or + + +).
Thirteen of the 14 patients with lipoatrophy had blood taken at the time of biopsy. Serum insulin-binding capacity was assayed by a second antibody coprecipitation assay specific for IgG antibody.6
Results are expressed in ug/l. For comparison we also included measurements of insulin-binding capacity from three other groups of patients: 17 newly diagnosed diabetics before treatment with insulin, 29 patients who had taken bovine soluble and isophane insulins for at least three years without developing lipoatrophy or insulin resistance, and 16 patients with insulin resistance (arbitrarily defined as taking over 120 units daily) (see fig 2) . contained diffuse IgG throughout the dermis, obscuring any specific localisation to blood vessel walls. Diffuse dermal IgG is often detected in skin biopsy samples examined by immunofluorescence. This does not necessarily indicate pathological change or correlate with the serum IgG concentration (WG Reeves, unpublished observations, 1979) . Five samples from the edge of lipoatrophic areas also showed mild granular deposition of immunological components (IgM, IgA, C3, or fibrin-fibrinogen) at the dermoepidermal junction. 
Results
There was wide variation in the types of insulin used by the patients with lipoatrophy ( the deeper dermis. Pigment-containing macrophages were often present, and iron was detected in deeper layers of the dermis. Examination of biopsy samples from the injection sites in two patients without lipoatrophy also showed mild perivascular infiltration, although the cells were predominantly polymorphonuclear (neutrophils and eosinophils) and often found in association with plasma cells.
Discussion
With the exception of hypoglycaemia, atrophy of subcutaneous fat at injection sites is the commonest complication of treatment with insulin. The observed incidence depends largely on the group studied, since lipoatrophy is thought to be commoner in younger patients and women.7 8 In susceptible people atrophy develops relatively soon after starting insulin: a mean of 269 days was recorded in Paley's series. 3 The pathogenesis of lipoatrophy has never been satisfactorily explained. dermis (fig 4) . The increased zinc concentration in lente and protamine zinc preparations or the presence of fish protamine in isophane and protamine zinc insulins may enhance the immunological response to injected insulin.18 The remarkable female preponderance in this and other series of patients with lipoatrophy is difficult to explain immunologically. Lipoatrophy may be more obvious in women, in whom there is more subcutaneous tissue available for dramatic change. Lipoatrophy at sites remote from injection, such as the breasts and face, has occasionally been reported and is difficult to explain by any theory of insulin-induced lipoatrophy. We think it much more likely that if such cases occur they represent the coexistence of insulin-dependent diabetes with some other form of lipodystrophy. 19 
